md

Anticytokinin activity was evaluated by 50% of the callus growth on the medium with kinetin but without anti-cytokinin

MD-222, a pioneering, highly potent PROTAC degrader targeting MDM2, efficiently mediates the rapid degradation of MDM2 protein and activates wild-type p53 within cells, showcasing significant anticancer effects[1][2].

MD 220661 is an inhibitor of semicarbazide-sensitive amine oxidase (SSAO), and a substrate of the enzyme.

MD-224 is a highly potent and efficacious MDM2 degrader based on the proteolysistargeting chimera (PROTAC) concept,and as a new class of anticancer agent.

MD-230254 is an inhibitor of MAO-B.

MD 780236 is a monoamine oxidase-B inhibitor.

MD13 is a macrophage migration inhibitor (MIF) oriented PROTAC (Ki value: 71 nM). MD13 can be used to study cancer.

MD2-IN-1 is a Myeloid differentiation protein 2 (MD2) inhibitor with a KD of 189  μM for the recombinant human MD2 (rhMD2).

MDL 101146 is an orally active neutrophil elastase inhibitor.

MD15 is a negative control for MD13.

MD001 is a dual agonist of peroxisome proliferator-activated receptor α (PPARα) and PPARγ.1 It binds to PPARα and PPARγ (Kds = 9.55 and 0.14 μM, respectively) but does not bind to PPARβ/δ at concentrations up to 500 μM. It increases transcriptional activity of PPARα and PPARγ in a cell-based luciferase reporter assay when used at a concentration of 10 μM. MD001 (10 μM) increases expression of PPARα, PPARγ, and retinoid X receptor (RXR), as well as PPARα and PPARγ target genes, in HepG2 cells. It increases glucose consumption as well as expression of GLUT2 and GLUT4 in HepG2 and 3T3-L1 cells, respectively, in a concentration-dependent manner. MD001 (20 mg/kg) decreases levels of glucose, insulin, free fatty acids, triglycerides, LDL, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in blood and reduces the size and number of hepatic lipid droplets in diabetic db/db mice.References1. Kim, S.-H., Hong, S.H., Park, Y.-J., et al. MD001, a novel peroxisome proliferator-activated receptor α/γ agonist, improves glucose and lipid metabolism. Sci. Rep. 9(1), 1656 (2019). MD001 is a dual agonist of peroxisome proliferator-activated receptor α (PPARα) and PPARγ.1 It binds to PPARα and PPARγ (Kds = 9.55 and 0.14 μM, respectively) but does not bind to PPARβ/δ at concentrations up to 500 μM. It increases transcriptional activity of PPARα and PPARγ in a cell-based luciferase reporter assay when used at a concentration of 10 μM. MD001 (10 μM) increases expression of PPARα, PPARγ, and retinoid X receptor (RXR), as well as PPARα and PPARγ target genes, in HepG2 cells. It increases glucose consumption as well as expression of GLUT2 and GLUT4 in HepG2 and 3T3-L1 cells, respectively, in a concentration-dependent manner. MD001 (20 mg/kg) decreases levels of glucose, insulin, free fatty acids, triglycerides, LDL, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in blood and reduces the size and number of hepatic lipid droplets in diabetic db/db mice. References1. Kim, S.-H., Hong, S.H., Park, Y.-J., et al. MD001, a novel peroxisome proliferator-activated receptor α/γ agonist, improves glucose and lipid metabolism. Sci. Rep. 9(1), 1656 (2019).

MD2-TLR4-IN-1 is a myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4) complex inhibitor.

2MD, an orally active vitamin D analog, both stimulates periosteal bone formation and decreases trabecular bone resorption, effectively restoring trabecular and cortical bone mass and strength. Additionally, 2MD regulates genes related to intraocular pressure (IOP) and reduces IOP in non-human primates [1] [2].

MIF degrader MD13 is involved in protein-protein interactions that play key roles in inflammation and cancer. Current strategies to develop small molecule modulators of MIF functions are mainly restricted to the MIF tautomerase active siteMIF degrader MD13. MD13 also exhibits antiproliferative effect in a 3D tumor spheroid model. In conclusion, we describe the first MIF-directed PROTAC (MD13) as a research tool, which also demonstrates the potential of PROTACs in cancer therapy.

Remdesivir (GS-5734) is a nucleoside analog, a broad-spectrum antiviral compound that exerts its activity by inhibiting the RNA-dependent RNA polymerase of viruses. Remdesivir is active against Ebola, SARS, and MERS viruses, and is potentially therapeutic against COVID-19.

Mdivi-1 (Mitochondrial division inhibitor 1) is a mitochondrial division inhibitor that inhibits DRP1 and Dynamin I (IC50=1-10 μM). Mdivi-1 inhibits mitochondrial autophagy.

Nepetalactone is found in the plant Nepeta parnassica and has high mosquito repellency properties.

Linaclotide acetate is used as an oral guanylate cyclase C agonist linaclotide; 14 amino acid peptide for the potential treatment of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation.

p53-Mdm2 inhibitor 4 inhibits the p53-MDM2 protein-protein interaction.

MDK-4025 is an inhibitor of the high voltage-activated (HVA) Ca2+ current in pyramidal neurons.

AMD-070 hydrochloride is a CXCR4 antagonist, is useful for Anti HIV.

EMD57439 is a selective PDE-III inhibitor, showing no significant increase in c-AMP concentration and producing little change in Ca(50).

OMDM-5 is a selective anandamide cellular uptake (ACU)inhibitor(Ki of 4.8 μM).

Dalzanemdor (SAGE-718) is an NMDA receptor-positive modulator of metabolism that can be used to study Huntington's chorea, Alzheimer's disease, and cognitive dysfunction.

MDK-6983 (MDK-6983) is an inhibitor of autophagy and disrupts the dynamics of actin cytoskeleton in human melanoma cells.

ENMD-1068 HCl (ENMD 1068) is a PAR-2 antagonist. ENMD-1068 HCl inhibits the development of endometriosis in a mouse model.

EMD57033 is a cardiac troponin C (cTnC) activator, a dominant Ca2+ sensitizer, which functions by binding to cardiac/slow skeletal troponin C heterodimers to promote cardiac contraction.

EMD 56551 is a selective small molecule 5-HT1A receptor agonist with anxiolytic activity for the study of anxiety disorders.

EMD-503982 is a potential Factor Xa and Factor VIIa inhibitor with potential anticancer and antitumor activity for the study of thromboembolic and neurological disorders.

EMDT oxalate is a selective 5-HT6 agonist, and has antidepressant effects.

AMDE-1 is an autophagy modulator and triggers autophagy in an Atg5-dependent manner. AMDE-1 recruits Atg16 to the pre-autophagosomal site and causes LC3 lipidation.

OMDM-6 is a dual agonist of TRPV1(EC50 = 75 nM) and CB1 (Ki = 3.2 μM). OMDM-6 inhibits anandamide cellular uptake with a Ki of 7.0 μM.

TCMDC-135051 is a potent and selective PfCLK3 protein kinase inhibitor demonstrating significant antiparasiticidal activity (EC50=320 nM) while exhibiting minimal off-target toxicity. It effectively hinders the transition from trophozoite to schizont, impairs transcription, and diminishes transmission to the mosquito vector.

EMD 527040 hydrochloride is an effective integrin αVβ6 inhibitor. The IC 50 values of EMD 527040 hydrochloride were 6 nM and 1.6 μM to inhibit αVβ6 binding to fibronectin and αVβ6 expression cells to fibronectin, respectively. EMD 527040 hydrochloride shows antifibrotic activity in animal models of biliary fibrosis and is active in vivo.

iMDK quarterhydrate is a potent PI3K inhibitor that inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate synergistically inhibits non-small cell lung cancer (NSCLC) with MEK inhibitors without harming normal cells and mice.

ENMD-119 is a 2-methoxyestradiol analog with antiproliferative and antiangiogenic activity. It is suitable for inhibiting HIF-1α and STAT3 in human HCC cells.

Nelonemdaz (Neu2000) is an NMDA receptor antagonist with antioxidant activity and neuroprotective activity used in the study of cerebral infarction reperfusion injury and acute ischemic stroke.

Cinepazide is a vasodilator used for the treatment of cardiovascular, cerebrovascular, and peripheral vascular diseases. Cinepazide acts as a potentiator of adenosine A2 receptors.

CAY10398 is a compound that serves as an isoform-selective inhibitor of histone deacetylase (HDAC1).

Cimoxatone is used as a Monoamine Oxidase Inhibitor.

Toloxatone (MD 69276) is a reversible monoamine oxidase A (MAOA) inhibitor.

Antioxidant 1024 (MD 1024) is an antioxidant agent and metal deactivator.

Argatroban (MCI-9038), a specific thrombin inhibitor, which is a non-heparin anticoagulant, prevents the formation of thrombi.

Cinepazide maleate (MD-67350), a maleate salt form of cinepazide, is a vasodilator.

Hisphen shows antileukemic activity.

Befloxatone is a potent, selective and reversible inhibitor of monoamine oxidase A.

MDCG sodium (N-methyl-N-dithiocarboxyglucamine sodium) is a metal chelator that promotes biliary excretion of Cd.

N-Methyl-D-aspartic acid is an amino acid that, as the D-isomer, is the defining agonist for the NMDA (N-Methyl-D-aspartic acid) receptor subtype of glutamate receptors.

IMD-0354 (IKK2 Inhibitor V) is an IKKβ inhibitor and inhibits IκBα phosphorylation in NF-κB pathway.

OMDM-1 ((Z)-N-[(2S)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]octadec-9-enamide) is a selective and metabolically stable anandamide cellular uptake (ACU)inhibitor with a Ki of 2.4 μM.